You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Spread of the idea of ‘deprescribing’ in China
  1. Zhihua Zheng1,
  2. Hongbing Huang2,
  3. Yong Wang1,
  4. Jinghao Wang3
  1. 1 Guangdong Province Pharmaceutical Association, Guangzhou, China
  2. 2 State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China
  3. 3 Department of Pharmacy, Jinan University First Affiliated Hospital, Guangzhou, China
  1. Correspondence to Dr Zhihua Zheng, Guangdong Province Pharmaceutical Association, Guangzhou 510080, China; snownotrace{at}126.com

https://doi.org/10.1136/ejhpharm-2019-001907

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    During 22–24 March 2017 we participated in the 22nd Congress of the European Association of Hospital Pharmacists (EAHP) where we came across the idea of ‘deprescribing’ presented by Barbara Farrell from Canada. We were so impressed by this idea, realising that ‘deprescribing’ is an important part of the Medication Therapy Management service, which was promoted in China by the Guangdong Province Pharmaceutical Association (GDPA) working with the American Pharmacists Association.1 In order to introduce ‘deprescribing’ into China, after we came back from the Congress we searched the literature on ‘deprescribing’ and wrote a review on it which was published in the journal Pharmacy Today,2 the official journal of the GDPA. Because …

    View Full Text

    Footnotes

    • Contributors ZZ planned and wrote the manuscript. HH, YW and JW collected the data and reviewed the manuscript for critical content. All authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.